Clinical pathways (CPWs) are a common component in the quest to improve the quality of health1. They are used to reduce variation, improve quality of care, and maximize the outcomes for specific groups of patients1. The development of a clinical pathway involves a structured multidisciplinary plan of care1. This process includes translating guidelines or evidence into local structures1.
Therefore, during the development of a clinical pathway, a quality professional should consult peer-reviewed evidence. This is because the evidence forms the basis of the guidelines that are translated into the local structures during the development of the clinical pathway1. This ensures that the care provided is based on the most current and best practice, leading to improved patient outcomes2.
It's important to note that while evaluating peer review committee findings, implementing best practice alerts, and gathering patient outcome data can be part of the overall quality improvement process, they are not specifically part of the development of a clinical pathway34. These activities may occur before or after the development of the clinical pathway but are not integral to the development process itself34.

The Malcolm Baldrige National Quality Award is the highest level of national recognition that a
U.S. organization can receive for performance excellence1. The award criteria focus on eight performance dimensions: Leadership and Governance, Strategy, Operations, Operational Continuity, Workforce, Customers and Markets, Community Engagement, and Finance1.
To achieve the Malcolm Baldrige award, an organization must demonstrate organizational resilience and long-term success through favorable performance levels and trends, comparisons to competitors and industry benchmarks (as appropriate), and relevant metrics1. Therefore, reviewing the Malcolm Baldrige standards to determine organization alignment is the best demonstration that an organization has begun the work necessary to achieve the Malcolm Baldrige award.
While creating a team to revise operations to conform to the Malcolm Baldrige requirements (Option A) is a step in the process, it does not necessarily demonstrate that the organization has begun the work necessary to achieve the award. The same applies to developing a crosswalk between Malcolm Baldrige and Joint Commission requirements (Option B) and determining effects on CMS Conditions of Participation (Option C).
These actions could be part of the process, but they do not directly demonstrate that the organization has begun the work necessary to achieve the Malcolm Baldrige award.
Beginning work toward achieving the Malcolm Baldrige National Quality Award necessitates a comprehensive understanding of the criteria and how an organization currently aligns with them. This would involve a thorough review of the Baldrige Excellence Framework, which includes the standards for performance excellence. By assessing current practices against the Baldrige criteria, an organization can identify areas of strength and opportunities for improvement. This review serves as a foundational step in the Baldrige journey, guiding the development of a detailed action plan to address gaps and enhance performance.
References:The Baldrige Performance Excellence Program provides a framework for organizations to improve performance and achieve excellence. The NAHQ references the Baldrige framework as a comprehensive standard for quality that healthcare organizations can aspire to and align with as part of their continuous quality improvement efforts.

* The first step for a quality improvement professional who believes that their MRSA facility rates are high is to contact the infection control practitioner to obtain benchmark data. Benchmark data are comparative data that can help identify gaps in performance and set realistic and achievable goals for improvement 1. Benchmark data can beobtained from various sources, such as national or regional databases, professional organizations, peer-reviewed literature, or other similar facilities 2.
* By contacting the infection control practitioner, the quality improvement professional can access reliable and valid data on MRSA rates in their facility and compare them with other facilities or standards. This can help them determine the magnitude and significance of the problem, and whether it warrants further investigation and action. The infection control practitioner can also provide guidance on the best practices and protocols for preventing and controlling MRSA infections, and the potential risk factors and causes of high MRSA rates 3.
* The other options are not the best first steps for the quality improvement professional. Reporting the concerns to senior management and the Quality Council (option B) may be premature and unnecessary without having sufficient evidence and analysis of the problem. Forming a quality improvement team (option C) may be helpful later in the process, but not before defining and measuring the problem.
Repeating the data collection process to justify the new rate (option D) may be wasteful and inaccurate, as it may not account for the variability and trends in the data, and it may not address the underlying causes of the problem . References:
* 1: NAHQ Healthcare Quality Competency Framework, Domain 5: Data Analytics, Skill 5.1.1
* 2: Benchmarking in Healthcare: A Practical Approach | NAHQ
* 3: Success and failures in MRSA infection control during the COVID-19 pandemic | Antimicrobial Resistance & Infection Control | Full Text 2
* : NAHQ Healthcare Quality Competency Framework, Domain 3: Performance and Process Improvement, Skill 3.1.1

The question is about the type of waste that should be recorded when a pharmacy's compounding process consistently yields more drug than is needed. This excess is stored until it is used or expired. In the context of waste in healthcare, this scenario is a clear example of overproduction. Overproduction refers to situations where more product is produced than is required at that time. This is a form of waste because it leads to unnecessary storage and potential disposal if the product expires or becomes obsolete1.
References:
https://www.leanblog.org/eight-types-of-waste-in-healthcare/

* Failure mode and effects analysis (FMEA) is a tool for conducting a systematic, proactive analysis of a process in which harm may occur12.
* In an FMEA, a team representing all areas of the process under review convenes to predict and record where, how, and to what extent the system might fail12.
* FMEA is used to identify all possible failures in a design, a manufacturing or assembly process, or a product or service, and to study the consequences of those failures2.
* FMEA is a prospective assessment that identifies and improves steps in a process and reasonably ensures a safe and clinically desirable outcome1.
* FMEA is a common process analysis tool that can help healthcare quality professionals to prevent errors, reduce variation, and improve patient safety1234.
* FMEA is applied when a new or modified process, function, or service with an associated hazard has not yet been implemented, or when improvement goals are planned for an existing process, function, or service2.
* FMEA procedure involves the following steps2:
* Assemble a cross-functional team of people with diverse knowledge about the process, product, or service, and customer needs.
* Identify the scope and boundaries of the FMEA.
* Fill in the identifying information at the top of the FMEA form.
* Brainstorm potential failure modes and their causes and effects.
* Assign a risk priority number (RPN) to each failure mode based on the severity, occurrence, and detectability of the failure.
* Prioritize the failure modes for action based on the RPNs.
* Identify and implement corrective actions to eliminate or reduce the high-risk failure modes.
* Evaluate the results and monitor the effectiveness of the actions.
* Update the FMEA as needed. References: 1: Failure Modes and Effects Analysis - Ministry of Health 2: What is FMEA? Failure Mode & Effects Analysis | ASQ 3: Failure Mode and Effects Analysis | Digital Healthcare Research 4: Healthcare FMEA | Healthcare Failure Mode & Effects Analysis - Quality-One